Core Viewpoint - Company is focused on global expansion while acknowledging challenges such as cultural differences and complex regulations in international markets [2] Group 1: Financial Performance - In Q1 2025, the company reported a main revenue of 205 million, an increase of 18.07% year-on-year, and a net profit of 31.27 million, up 34.21% year-on-year [10] - The increase in net profit was lower than revenue growth due to significant differences in cash management income and foreign exchange gains compared to the same period in 2023 [3] - The company aims to enhance profitability to ensure that net profit growth exceeds revenue growth in the future [4] Group 2: Market Strategy - Company is actively expanding in the domestic market by leveraging national policies, enhancing product localization, and optimizing market strategies to increase market share and profitability [8][9] - The company has established a strong market presence and brand recognition in Europe and the US, while also facing challenges in international market penetration [2] Group 3: Research and Development - The company is increasing investment in R&D, particularly in key technologies and forward-looking innovations, to enhance its competitive edge [5] - The company plans to strengthen its equipment R&D to improve product quality and market competitiveness, despite the low gross margin of equipment [4][6] Group 4: Operational Developments - A new production park is set to commence construction this year, with the goal of completing major production facilities by next year to support ongoing growth [7]

Group 1: Market Expansion and Challenges - The company has developed a methodology for market expansion and has established strong competitiveness and brand recognition in the European and American markets [2] - Challenges in international market expansion include cultural differences, complex legal regulations, and localization operations [2] - The company is actively promoting international management and researching target market conditions to enhance competitiveness and profitability [2] Group 2: Financial Performance and Cost Management - The net profit growth rate for 2024 was lower than the revenue growth rate due to significant differences in cash management income and exchange gains/losses compared to 2023 [3] - The increase in sales expense ratio is attributed to the acquisition of a South Korean company and increased marketing and travel expenses for deep market development [3] - Measures are being taken to enhance profitability, ensuring that future net profit growth exceeds revenue growth [3] Group 3: R&D and Product Development - The company aims to increase investment in equipment R&D despite low gross margins, focusing on providing integrated solutions in the dental field [3] - The company plans to enhance R&D competitiveness by establishing laboratories in advantageous regions and increasing investment in key technologies [6] - Emphasis is placed on protecting intellectual property and aligning technological innovations with market demands [6] Group 4: Domestic Market Strategy - The company holds a positive attitude towards domestic market expansion, leveraging national policies and enhancing product competitiveness [5] - Strategies include optimizing market approaches and responding to policy changes to increase market share and profitability [5] Group 5: New Production Facilities - A new production park is set to commence construction, with the goal of completing major production workshops this year and starting production next year [4] Group 6: Material Cost Management - The company believes that the cost reduction potential for zirconia materials is limited, emphasizing product quality and maintaining a healthy supply chain [7] - High-value-added product development is prioritized to enhance performance and quality, thereby improving competitiveness and profitability [8]

证券代码：301580 证券简称：爱迪特 公告编号：2025-021 特别提示： 本次上市流通的限售股为爱迪特（秦皇岛）科技股份有限公司（以下简称"爱 迪特"或"公司"）首次公开发行前已发行部分股份。 本次解除股份限售的股东户数共计 17 名，解除限售股份数量为 45,375,858 股，占公司总股本 42.58%。限售期为自公司首次公开发行上市之日起 12 个月。 爱迪特（秦皇岛）科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次拟解除限售的股份上市流通日期为 2025 年 6 月 26 日（星期四）。 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意爱迪特（秦皇岛）科技股份有限公司 首次公开发行股票注册的批复》（证监许可20232615 号）同意，公司首次公开 发行新股 19,029,382 股，于 2024 年 6 月 26 日在深圳证券交易所上市交易。 首次公开发行前公司总股本为 57,088,145 股，首次公开发行股票完成后公司 总股本为 76,117,527 股，其中无流通限制或 ...

中信建投证券股份有限公司 经中国证券监督管理委员会《关于同意爱迪特（秦皇岛）科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕2615 号）同意，公司首次公开发 行新股 19,029,382 股，于 2024 年 6 月 26 日在深圳证券交易所上市交易。 首次公开发行前公司总股本为 57,088,145 股，首次公开发行股票完成后公司总 股本为 76,117,527 股，其中无流通限制或限售安排股票数量为 18,047,627 股，占发 行后总股本的比例为 23.71%，有流通限制或限售安排股票数量为 58,069,900 股，占 发行后总股本的比例为 76.29%。 2024 年 12 月 26 日，公司首次公开发行网下配售限售股上市流通，股份数量为 981,755 股，占公司总股本的 1.29%，具体内容详见公司于 2024 年 12 月 24 日在巨 潮资讯网（www.cninfo.com.cn）上披露的《首次公开发行网下配售限售股上市流通 提示性公告》（公告编号：2024-028）。 （二）上市后股本变动情况 2025 年 6 月 10 日，公司实施了 2024 年度权益分派，以公 ...

证券代码：301580 证券简称：爱迪特 公告编号：2025-021 爱迪特（秦皇岛）科技股份有限公司 关于首次公开发行前部分已发行股份上市流通提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次上市流通的限售股为爱迪特（秦皇岛）科技股份有限公司（以下简称"爱 迪特"或"公司"）首次公开发行前已发行部分股份。 本次解除股份限售的股东户数共计 17 名，解除限售股份数量为 45,375,858 股，占公司总股本 42.58%。限售期为自公司首次公开发行上市之日起 12 个月。 本次拟解除限售的股份上市流通日期为 2025 年 6 月 26 日（星期四）。 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意爱迪特（秦皇岛）科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2023]2615 号）同意，公司首次公开 发行新股 19,029,382 股，于 2024 年 6 月 26 日在深圳证券交易所上市交易。 首次公开发行前公司总股本为 57,088,145 股，首次公开发行股票完成后公 ...

Core Viewpoint - The company, Aidi Te (爱迪特), is experiencing growth in its dental restoration materials business, driven by product innovation and expansion into overseas markets, as evidenced by its recent financial performance and strategic focus on digitalization and high-end products [5][6]. Group 1: Product Pricing and Market Demand - The pricing of zirconia products is primarily determined by product performance, stability, safety, and the supplier's reputation [2]. - The overseas market presents significant opportunities due to a large consumer base and diverse dental treatment needs, which encourages the company to seek new growth points [3]. Group 2: Financial Performance - In Q1 2025, the company reported a main revenue of 205 million yuan, an increase of 18.07% year-on-year, and a net profit of 31.27 million yuan, up 34.21% year-on-year [5]. - The company's gross profit margin stands at 51.0%, indicating strong profitability in its operations [5]. Group 3: Product Development and Cost Efficiency - The increase in gross margin for dental restoration materials is attributed to a shift towards high-end product series, ongoing R&D for competitive products, and enhanced production automation leading to cost advantages [4]. - 3D printing technology offers advantages over traditional methods, including improved material utilization, higher production precision, and reduced manual processing steps [5]. Group 4: Analyst Ratings and Predictions - Recent analyst ratings indicate a positive outlook for the stock, with two institutions issuing buy ratings [6]. - Financial forecasts suggest continued growth in net profit, with estimates reaching 2.62 billion yuan for 2025 [6].

Group 1: Product Pricing and Market Demand - The pricing of zirconia products is primarily determined by product performance, stability, and safety standards, which must meet strict clinical requirements [1] - The reputation and service quality of suppliers play a crucial role in customer purchasing decisions, with the company having established a strong market presence and customer trust [1] Group 2: Overseas Market Drivers - The overseas market presents a large consumer base and diverse dental treatment needs, providing significant opportunities for the company's diversified products and services [2] - Mature markets demand high product stability and standardization in denture processing, with a strong willingness to pay for advanced products like 3D printing and high-end zirconia [2] - Emerging markets still have substantial penetration potential for digitalization, presenting structural opportunities in the industry [2] Group 3: Profit Margin Improvement - The improvement in profit margins for dental restoration materials is attributed to the adjustment of product series, with a growing share of high-end gradient series products [3] - Continuous research and development of competitive products contribute to margin enhancement [3] - Increased shipment volumes and raw material procurement, along with enhanced production automation, lead to cost advantages and economies of scale [3] Group 4: Advantages of 3D Printing Technology - 3D printing significantly improves raw material utilization compared to traditional subtractive manufacturing methods [4] - Higher precision in production is achieved, addressing limitations in detail processing associated with traditional methods [4] - Additive manufacturing reduces manual steps in denture processing, accelerating production pace and enabling full-process digitalization [4]

证券代码： 301580 证券简称：爱迪特 公告编号： 2025-020 爱迪特（秦皇岛）科技股份有限公司 关于举办投资者开放日的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）为更好地与投资 者进行沟通交流，使广大投资者深入全面地了解公司情况，公司将于 2025 年 6 月 25 日举办投资者开放日活动，现将有关事项公告如下： 一、活动时间： 3、面对面交流：设置问答及互动环节，您可与公司管理层、技术专家 深入探讨，提出宝贵建议。 四、登记预约： 请参加现场调研的投资者于 2025 年 6 月 24 日 14:00 前扫描二维码报名， 以便公司做好活动接待登记和安排。 2025 年 6 月 25 日（星期三）08:50-13:30 二、活动地点： 河北省秦皇岛市经济技术开发区都山路 9 号爱迪特（秦皇岛）科技股 份有限公司 三、活动方式及内容： 活动采取现场接待的方式进行（含简餐），公司与参与活动的投资者进 行现场交流，并安排投资者对公司进行实地调研参观。 1、深度业务解读：分享公司战略规划、核心业务 ...

暗盘资金一眼洞悉庄家意图>> 牙科医疗板块盘初拉升，皓宸医疗（002622）封板涨停，爱迪特（301580）涨超5%，康惠制药 （603139）、悦心健康（002162）、正海生物（300653）、国瓷材料（300285）等均涨超2%。 ...

爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）董事会于近日 收到公司副总经理解万东先生提交的书面辞职报告，解万东先生因个人原因， 申请辞去公司副总经理职务，辞任后不再担任公司任何职务。解万东先生的辞 职报告自送达董事会之日起生效，其辞职不会对公司经营产生影响。 解万东先生原定任期届满日为 2027 年 4 月 8 日，截至本公告披露日，解万 东先生未直接持有公司股份，其通过持股平台同源（天津）企业管理中心（有 限合伙）间接持有公司股份 8 万股，占公司总股本的 0.105%，其配偶或其他关 联人未持有公司股份。解万东先生辞职后，其股份变动将严格遵守《深圳证券 交易所上市公司自律监管指引第 10 号——股份变动管理》《深圳证券交易所上 市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》《上市 公司董事和高级管理人员所持本公司股份及其变动管理规则（2025 年修订）》 等法律法规的要求以及在《首次公开发行股票并在创业板上市招股说明书》 《首次公开发行股票并在创业板上市之上市公告书》里所作出的承诺。 公司及董事会对解万东先生在任职期间的勤勉工作及对公司发展所作出的 贡献表示衷心感谢。 特此公 ...